Bayer has reported that finerenone significantly delayed kidney disease progression in patients with non-diabetic chronic kidney disease (CKD) in its phase 3 FIND-CKD trial.
The oral drug led to a statistically-significant reduction in kidney decline compared to a placebo. It also demonstrated an improvement in the estimated glomerular filtration rate (eGFR) slope from baseline to month 32. eGFR is a predictive metric for the risk of kidney failure.
A non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), finerenone already has FDA approval for reducing kidney function decline and failure, heart attacks, and heart failure in adults with chronic kidney disease associated with type 2 diabetes. However, patients with non-diabetic CKD currently have few options for treatment.
FIND-CKD is the fifth phase 3 study to meet its primary endpoint and the largest phase 3 clinical trial to test the efficacy of finerenone on non-diabetic CKD. It used a broad patient population with various ethologies, including hypertension and glomerulonephritis.